Solitek is proud to announce that our co-founder, Víctor M. Díaz Pérez, has been invited to join the prestigious editorial boards of PharmaFocus Europe, PharmaFocus America, and PharmaFocus Asia. This invitation marks a significant milestone in Victor’s career and reflects his expertise and dedication to advancing the pharmaceutical industry.
Víctor M. Díaz Pérez, who also serves as the Operations Director at Solitek, is honored to accept this role. Being part of the editorial boards for these renowned publications is not only a privilege but also a responsibility that Victor embraces wholeheartedly. As a board member, he is committed to upholding and enhancing the high standards of editorial content that PharmaFocus is known for, contributing to the dissemination of valuable insights and information that benefit the global pharmaceutical community.
“I am truly humbled by this opportunity to work alongside some of the most respected voices in our field,” said Victor. “I look forward to collaborating with the editorial teams and fellow board members to support the mission of PharmaFocus in delivering cutting-edge content that informs and inspires professionals across the industry.”
The PharmaFocus publications are recognized as leading sources of knowledge and analysis in the pharmaceutical sector, providing in-depth coverage of the latest trends, research, and innovations. Victor’s inclusion on the editorial boards is a testament to his extensive experience and his commitment to fostering excellence in pharmaceutical research and development.
Solitek extends its sincere thanks to the teams at Ochre Media for this distinguished invitation. We are confident that Victor will make significant contributions to the continued success of PharmaFocus Europe, America, and Asia.
Victor also expresses his deep gratitude to all colleagues, partners, and friends for their unwavering support and encouragement as he embarks on this new journey. He is eager to begin contributing to the editorial direction of these influential publications and to play a part in shaping the future of pharmaceutical communications.
